European Patent Convention

Lleida.net obtains European patent on its method for registering content in blockchain transactions

Retrieved on: 
Wednesday, August 30, 2023
Blockchain, Intellectual property, Software as a service, Euronext Growth, Policy, European Patent Office, BME Growth, Certification, Patent, European Patent Convention, Growth, OTCQX, Content, Cryptocurrency

MADRID, Spain, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Spanish listed company Lleida.net (OTC.US) (ALLLN.PA) (LLN.MA) has been granted a European patent for its Method for Certifying the Content of Blockchain Transactions.

Key Points: 
  • MADRID, Spain, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Spanish listed company Lleida.net (OTC.US) (ALLLN.PA) (LLN.MA) has been granted a European patent for its Method for Certifying the Content of Blockchain Transactions.
  • The recognition is valid for 20 years and bears the number EP3761207, which is granted by the European Patent Office.
  • The patent covers one of the main problems of blockchain networks and the blockchain industry which is the reliability of content entered into the network.
  • The method offers a way to immutably record messaging data in a blockchain ledger for traceability and trust purposes.

Huawei and Ericsson Sign Long-Term Patent Cross-Licensing Agreement

Retrieved on: 
Friday, August 25, 2023
ITU, IEEE, 3GPP, ICT, Wi-Fi, European Patent Office, IETF, SEP, Patent, Ericsson, European Patent Convention, Mobile phone, Huawei

"We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.

Key Points: 
  • "We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.
  • "As major contributors of standard essential patents (SEPs) for mobile communication, the companies recognize the value of each other's intellectual property, and this agreement creates a stronger patent environment.
  • In 2022, Huawei topped the European Patent Office's applicant ranking for number of patent applications filed, with 4,505 applications.
  • Fan said, "This agreement is the result of intensive discussions that ensured the interests of both patent holders and implementers are served fairly."

Huawei and Ericsson Sign Long-Term Patent Cross-Licensing Agreement

Retrieved on: 
Friday, August 25, 2023
ITU, IEEE, 3GPP, ICT, Wi-Fi, European Patent Office, IETF, SEP, Patent, Ericsson, European Patent Convention, Mobile phone, Huawei

"We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.

Key Points: 
  • "We are delighted to reach a long-term global cross-licensing agreement with Ericsson," said Alan Fan, Head of Huawei's Intellectual Property Department.
  • "As major contributors of standard essential patents (SEPs) for mobile communication, the companies recognize the value of each other's intellectual property, and this agreement creates a stronger patent environment.
  • In 2022, Huawei topped the European Patent Office's applicant ranking for number of patent applications filed, with 4,505 applications.
  • Fan said, "This agreement is the result of intensive discussions that ensured the interests of both patent holders and implementers are served fairly."

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

Retrieved on: 
Wednesday, August 23, 2023
Drug development, European Patent Bulletin, Opposition procedure before the European Patent Office, Pathology, ASX, Brain, ATH, Treating, Patent, Iron, SAN, European Patent Convention, Therapy, Disease, Pharmaceutical industry, Alterity

MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent.

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the European Patent Office has granted Alterity a new composition of matter patent.
  • The patent secures broad protection over a new class of iron chaperone drug candidates for treating major neurodegenerative diseases.
  • “Through restoration of normal iron balance in the brain, we have the potential to slow disease progression of diseases including Parkinson’s and Alzheimer’s.
  • The composition of matter patent covers more than 150 novel pharmaceutical compositions that are designed to redistribute the excess iron implicated in neurodegenerative diseases.

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Retrieved on: 
Wednesday, August 23, 2023
Patent, Acute decompensated heart failure, IV, Heart failure, Cardiogenic shock, Windtree Therapeutics, HEART, Heart, European Patent Office, LIKE, European Patent Convention, Therapy, Pharmaceutical industry

The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.

Key Points: 
  • The new composition of matter patent, titled: “17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE,” provides patent protection through late 2039.
  • The newly issued patent follows the Company’s announcement in April 2023 that the European Patent Office granted Patent No.
  • 3599243, which also provides patent coverage for the dual mechanism SERCA2a Activator class of drug candidates.
  • Istaroxime and these follow-on SERCA2a Activators look to deliver on the potential of SERCA2a activation in heart failure.

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, FDA, Other Health, Health, General Health, Health Technology, Other Science, Medical Devices, Research, Science, Clinical Trials, 1836 U.S. Patent Office fire, Patent, Temperature, NDRA, European Patent Convention, Radio, Sound, Skin, Calibration, Medical imaging

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe.

Key Points: 
  • ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe.
  • ENDRA’s intellectual property portfolio now includes 67 issued patents worldwide, providing protection for the TAEUS® system with its novel hybrid ultrasound and thermoacoustic imaging technology.
  • The following three patents strengthening the TAEUS system’s proprietary position were issued:
    U.S. Patent No.
  • 11730374, titled “Radio Frequency Applicator for a Thermoacoustic Imaging System,” relates to a novel radio frequency applicator with an integrated wedge.

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Retrieved on: 
Thursday, August 17, 2023
Intellectual property, HSCS, Cardiovascular disease, Heart, European Patent Office, ECG, EPO, Death, Patent, European Patent Convention, Artificial intelligence, United, AI, Medical device

Southlake, TX, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that it has been issued a notice of patent allowance from the European Patent Office.

Key Points: 
  • Southlake, TX, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that it has been issued a notice of patent allowance from the European Patent Office.
  • To date, HeartSciences has been granted or allowed 41 patents including 9 in the United States.
  • Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of ECG’s are performed worldwide every week and the ECG is by far the most ubiquitous cardiac test.
  • This latest patent further expands our international coverage and is the latest addition to our extensive patent portfolio.”

IGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical Trials

Retrieved on: 
Monday, August 14, 2023
Cannabis, Health, Agriculture, Natural Resources, Clinical Trials, Pharmaceutical, Commissioner, Seizure, SG, European Patent Office, Premenstrual syndrome, Cannabinoid, Woman, Research, Sale, Research and development, Alzheimer's disease, PMS, Patient, European Patent Convention, IGC, Growth, Sleep, NYSE, Agitation, Pharmaceutical industry, Fine chemical, Cryptocurrency

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended June 30, 2023, which is the first quarter of the Company’s 2024 fiscal year.

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended June 30, 2023, which is the first quarter of the Company’s 2024 fiscal year.
  • Throughout the quarter, IGC Pharma maintained substantial momentum in the development of a Phase 3 manufacturing facility located on the West Coast, including augmentation of distillation capacity.
  • Ram Mukunda, Chief Executive Officer of IGC Pharma, commented, “Our first fiscal quarter of 2024 was highlighted by substantial progress in our efforts to advance our lead drug asset, IGC-AD1, through Phase 2 clinical trials on Alzheimer’s.
  • However, the Company expects R&D expenses to increase from the current levels as enrollment in the Phase 2 trial expands.

Elevate Your Patent Game: Advanced Drafting Techniques for Successful EPO (European Patent Office) Patent Applications Training Course (London, UK - November 10, 2023)

Retrieved on: 
Friday, August 18, 2023
Daniel, International Patent Institute, IIB, Mechanics, Success, Electronics, DG2, Disclosure, The Hague, University, Representation before the European Patent Office, Computer, Marketing Research Institute International, EPO, CEIPI, Patent, European Patent Convention, Physics, Knowledge, DG1, Industrial design

DUBLIN, Aug. 18, 2023 /PRNewswire/ -- The "Advanced Drafting Techniques for Successful EPO (European Patent Office) Patent Applications Training Course" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 18, 2023 /PRNewswire/ -- The "Advanced Drafting Techniques for Successful EPO (European Patent Office) Patent Applications Training Course" conference has been added to ResearchAndMarkets.com's offering.
  • Many patent applications and patents are lost before the EPO, either before Opposition Divisions or before Appeal.
  • The interplay between Art 83, Art 84 and Art 56
    Daniel X. Thomas is an electronics engineer by training.
  • Although he retired from active service at the EPO on 1 January 2013, Daniel continues to be active in the field of training patent specialists.

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Communication, De novo, Classification, Nucleotide, UTI, European Patent Office, Infection, Curetis, Thermo Fisher Scientific, AMR, IP, Sale, Nadine Opgen-Rhein, Single-nucleotide polymorphism, Urinary tract infection, Patent, SNP, Medicine, European Patent Convention, Plasmid, IVD, FDA, Ares, Pneumonia, Video game, Pharmaceutical industry, Q2

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results.
  • Second Quarter 2023 and First Half 2023 Financial Results of OpGen, Inc.
    Total revenue for the second quarter of 2023 was approximately $0.7 million compared to the company’s revenue of approximately $1.0 million in the second quarter of 2022, which was primarily driven by the one-time sale of a pool of Unyvero instrument systems to Menarini in Q2-2022.
  • Total operating expenses decreased in the second quarter of 2023 to approximately $5.9 million compared to approximately $6.2 million for the second quarter of 2022.
  • ET, to review the second quarter 2023 financial results and business activities, but will not be taking any questions.